Breaking News Instant updates and real-time market news.

WBA

Walgreens Boots Alliance

$73.35

-2.12 (-2.81%)

, GOOG

Alphabet

$1,023.33

-5.46 (-0.53%)

18:43
12/19/18
12/19
18:43
12/19/18
18:43

Walgreens, Verily form partnership to improve health outcomes

Walgreens Boots Alliance (WBA) and Verily, an Alphabet (GOOG) company, announced they will collaborate on multiple projects under a broad agreement aimed at improving health outcomes for patients with chronic conditions, while also lowering the cost of care. Walgreens will be a first-choice retail pharmacy development and commercialization partner to Verily, and the organizations have agreed to work on and explore ways to improve access to advanced healthcare technologies and solutions - which may include sensors and software to help prevent, manage, screen and diagnose disease - with a shared goal of scaling deployment at Walgreens retail locations. Initially, the companies are developing a medication adherence pilot project that will deploy devices and other approaches designed to improve adherence. Walgreens together with Onduo, Verily's joint venture with Sanofi (SNY), will also launch a virtual diabetes solution to Walgreens employees and family members with Type 2 diabetes through the Walgreens employee health plan. Onduo provides tools, coaching and remote access to specialty doctors to help people with diabetes to manage their condition anytime, anywhere. These initiatives are part of a broader strategic alliance designed to combine Verily's healthcare technology innovation with Walgreens corner store presence and trusted pharmacy services.

WBA

Walgreens Boots Alliance

$73.35

-2.12 (-2.81%)

GOOG

Alphabet

$1,023.33

-5.46 (-0.53%)

GOOGL

Alphabet Class A

$1,034.93

-8.38 (-0.80%)

SNY

Sanofi

$43.41

0.2 (0.46%)

  • 20

    Dec

  • 17

    Jan

  • 28

    Jan

  • 03

    Mar

  • 11

    Mar

  • 22

    Mar

  • 28

    Apr

WBA Walgreens Boots Alliance
$73.35

-2.12 (-2.81%)

12/19/18
WOLF
12/19/18
INITIATION
WOLF
Peer Perform
Walgreens Boots Alliance assumed with a Peer Perform at Wolfe Research
12/14/18
12/14/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Walgreens Boots Alliance (WBA) downgraded to Sell from Neutral at Goldman Sachs with analyst Robert Jones saying he struggles to make a "compelling fundamental case" for the Americas Healthcare Services Supply Chain heading into 2019 as "issues facing core growth drivers do not seem to be abating." 2. Cisco (CSCO) downgraded to Neutral from Buy at Nomura Instinet with analyst Jeffrey Kvaal saying strengthening information technology spending, an innovation-led refresh cycle, and a rising software mix have lifted Cisco's multiple and its shares to post-recession highs. 3. Universal Health (UHS) downgraded to Sell from Neutral at Goldman Sachs with analyst Stephen Tanal saying a "healthy" macro environment helps acute hospitals' commercial mix, but behavioral health providers like Universal Health over-index to Medicaid and Medicare, "leaving them less exposed to the supportive backdrop." 4. Beacon Roofing (BECN) downgraded to Neutral from Outperform at Wedbush with analyst Jay McCanless saying that yesterday's investor day did not provide any new catalysts to raise EPS estimates or price target. 5. Kaman (KAMN) downgraded to Underweight from Neutral at JPMorgan with analyst Seth Seifman saying he values the stock at 14 times his 2020 earnings per share estimate of $4.05 while adding 15c for potentially accretive M&A, given the company's balance sheet capacity. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
12/14/18
GSCO
12/14/18
DOWNGRADE
Target $68
GSCO
Sell
Goldman downgrades Walgreens to Sell with $68 target, sees downside in 2019
Goldman Sachs analyst Robert Jones downgraded Walgreens Boots Alliance (WBA) to Sell from Neutral and lowered his price target for the shares to $68 from $73. The analyst says he struggles to make a "compelling fundamental case" for the Americas Healthcare Services Supply Chain heading into 2019 as "issues facing core growth drivers do not seem to be abating." Jones sees limited "core" growth for the large-cap names amid persisting sales and margin pressures and as drug pricing remains a regulatory focus. He downgrades Walgreens to Sell saying challenges in its retail pharmacy business "have intensified, forcing the company to search for other avenues of growth." Jones also keeps a Neutral rating on CVS Health (CVS) and Sell rating on Rite Aid (RAD).
12/14/18
GSCO
12/14/18
DOWNGRADE
Target $68
GSCO
Sell
Walgreens Boots Alliance downgraded to Sell from Neutral at Goldman Sachs
Goldman Sachs analyst Robert Jones downgraded Walgreens Boots Alliance to Sell and lowered his price target for the shares to $68 from $73.
GOOG Alphabet
$1,023.33

-5.46 (-0.53%)

12/03/18
STFL
12/03/18
NO CHANGE
Target $190
STFL
Hold
After proxy, Stifel says Google could come back with bid for Red Hat
After Red Hat (RHT) filed a proxy on Friday evening related to its pending acquisition by IBM (IBM) that mentioned three other parties interested in a potential purchase, Stifel analyst Brad Reback said he believes that "Party A" in the filing is Microsoft (MSFT), that "Party B" is Google (GOOGL) and that "Party C" is Amazon (AMZN). If he is correct with that assessment of the identities of the parties, it is a clear indication that Red Hat shopped itself to the "logical players" during the negotiation process, said Reback, who believes there is still a chance Google may come back and make a bid for Red Hat given the change of leadership in the Google Cloud unit. The analyst, who views Red Hat as a unique asset with strong enterprise relationships, hybrid cloud capabilities, and an open source heritage, keeps a Hold rating and $190 price target on the stock given the existing deal with IBM.
12/06/18
GUGG
12/06/18
INITIATION
Target $1330
GUGG
Buy
Alphabet initiated with a Buy at Guggenheim
Guggenheim analyst Michael Morris initiated Alphabet with a Buy and $1,330 price target saying it has a unique combination of intellectual property, employee talent and financial resources that position it well for global growth beyond implied expectations.
12/06/18
12/06/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. LG Display (LPL) initiated with a Buy at Citi. 2. Twitter (TWTR) and Alphabet (GOOG, GOOGL) were initiated with a Buy at Guggenheim, while Snap (SNAP) and Facebook (FB) were initiated with a Neutral. 3. Apache (APA) initiated with an Overweight at Stephens. 4. CorMedix (CRMD) initiated with a Buy at Roth Capital. 5. Protagonist Therapeutics (PTGX) initiated with a Buy at Nomura Instinet. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
11/26/18
KEYB
11/26/18
NO CHANGE
KEYB
AWS revenue could double to $56B-plus by 2021, says KeyBanc
KeyBanc analyst Brent Bracelin notes that the annual November trek to Las Vegas for AWS (AMZN) reInvent commences on Tuesday. The analyst believes 2019 could mark the first year AWS adds an incremental $10B within a single year as cloud and digital transformation becomes a mainstream phenomena driving AWS revenue to $35B-plus and operating profits above $10B for the first time. Looking out three years to 2021, Bracelin estimates AWS revenue could double to an estimated $56B-plus from $25B this year. Even at that scale, this would assume AWS might capture just 4% share of a trillion-dollar market leaving ample room for IaaS alternative platforms like Microsoft Azure (MSFT) and Google Cloud (GOOG; GOOGL) to also sustain high-growth at scale, he contends. Bottom line, the analyst believes AWS is likely to remain a bright spot within the broad Amazon product portfolio from both a revenue growth and profitability perspective during a cloud-first era.
GOOGL Alphabet Class A
$1,034.93

-8.38 (-0.80%)

12/19/18
RHCO
12/19/18
NO CHANGE
Target $2400
RHCO
Buy
Booking Holdings room nights growth tracking above guidance, says SunTrust
SunTrust analyst Naved Khan kept his Buy rating and $2,400 price target on Booking Holdings (BKNG), saying his analysis of data through mid-December indicates that the company's room night growth is tracking "modestly above" the management's guidance. The analyst adds that he sees little impact from the riots in Paris on travel bookings and also views the "signs of a slight easing in competitive cadence on Google (GOOGL) meta positively for margins."
12/12/18
BOFA
12/12/18
NO CHANGE
Target $190
BOFA
Buy
Facebook testing search ads may unlock new revenue stream, says BofA/Merrill
BofA/Merrill analyst Justin Post kept his Buy rating and $190 price target on Facebook (FB), saying there is potential for "high value search activity" on its platform if its testing of search ads within the Marketplace section - as reported by TechCrunch - bears fruit. The analyst notes that the report anticipates the search ad testing to be rolled out with a small set of auto and e-commerce advertisers, modeling that the company could generate up to $5B in annual search related ad revenue under the assumption of offering a 75% discount to Google's (GOOGL) revenue per search. Post maintains his positive view on Facebook and its monetization opportunities.
SNY Sanofi
$43.41

0.2 (0.46%)

12/11/18
JEFF
12/11/18
UPGRADE
JEFF
Buy
Sanofi upgraded to Buy from Hold at Jefferies
Jefferies analyst Peter Welford upgraded Sanofi to Buy and raised his price target for the shares to EUR 90 from EUR 75. The analyst believes European large-cap pharmaceuticals are entering a period of sustained earnings momentum which should justify valuations above the historic average for the sector.
12/11/18
12/11/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. AT&T (T) upgraded to Buy from Neutral at Citi with analyst Michael Rollins saying he expects AT&T to further benefit from the "measured" promotional environment in wireless, while improving its competitive position from FirstNet and the marketing of its network enhancements, branded 5G Evolution. 2. Sanofi (SNY) upgraded to Buy from Hold at Jefferies with analyst Peter Welford saying he believes European large-cap pharmaceuticals are entering a period of sustained earnings momentum which should justify valuations above the historic average for the sector. 3. Total (TOT) upgraded to Buy from Neutral at BofA/Merrill. 4. Zynga (ZNGA) upgraded to Outperform from Neutral at Macquarie. 5. Allstate (ALL) upgraded to Hold from Sell at Edward Jones. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
12/11/18
GABE
12/11/18
NO CHANGE
GABE
Buy
Gabelli sees Clovis as likely takeout target, top biotech pick in 2019
Gabelli analyst Jing He highlights Clovis (CLVS) as his top biotech pick in 2019. With the Tesaro (TSRO) acquisition by GlaxoSmithKline (GSK), Clovis will become the only standalone PARP, which the analyst believes makes it the most likely takeout target in 2019. He continues to believe Bristol-Myers (BMY), Sanofi (SNY) and Roche (RHHBY) to be the most interested buyers. The analyst reiterates a Buy rating on Clovis' shares.
11/19/18
WELS
11/19/18
NO CHANGE
WELS
Pfizer price hikes may bring industry scrutiny, says Wells Fargo
Pfizer's (PFE) plans to raise prices on a host of medicines may put the drug industry "further in the crosshairs of an administration and Congress that is set on lowering drug prices," Wells Fargo analyst David Maris tells investors in a research note. The analyst points out that Pfizer earlier this year was criticized by the Trump administration for drug price increases, and as a result, it rolled the price increases back. However, Pfizer's new price increases "are not egregious" and its advance warning may be an attempt to see if minor price increases will also bring the administration's rebuke, says Maris. Nonetheless, given how public the administration's previous rebuke was, the analyst thinks Pfizer's confirmation Friday could "enflame the debate around drug pricing, especially since it comes less than two weeks following an election that resulted in Democrat control of the House with many having run on a drug-price-controls/Medicare-for-All platforms." Other large drugmakers include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Roche (RHHBY) and Sanofi (SNY).

TODAY'S FREE FLY STORIES

WHR

Whirlpool

$159.20

0.77 (0.49%)

13:37
10/15/19
10/15
13:37
10/15/19
13:37
Periodicals
AHAM reports U.S. appliance shipments down 4.5% in September, Bloomberg says »

The Association of Home…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

BAC

Bank of America

$29.95

0.8 (2.74%)

13:33
10/15/19
10/15
13:33
10/15/19
13:33
Recommendations
Bank of America analyst commentary  »

Wells Fargo positive on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

  • 12

    Nov

BRK.A

Berkshire Hathaway

$314,150.06

2587.06 (0.83%)

, BRK.B

Berkshire Hathaway

$209.40

1.55 (0.75%)

13:33
10/15/19
10/15
13:33
10/15/19
13:33
Periodicals
Buffett seeks Fed permission to boost Bank of America stake, Bloomberg reports »

Warren Buffett's…

BRK.A

Berkshire Hathaway

$314,150.06

2587.06 (0.83%)

BRK.B

Berkshire Hathaway

$209.40

1.55 (0.75%)

BAC

Bank of America

$29.95

0.8 (2.74%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

  • 12

    Nov

13:25
10/15/19
10/15
13:25
10/15/19
13:25
General news
FX Action: USD-JPY »

FX Action: USD-JPY…

ZM

Zoom Video

$69.34

-1.49 (-2.10%)

13:25
10/15/19
10/15
13:25
10/15/19
13:25
Conference/Events
Zoom Video to host analyst meeting »

Analyst meeting to be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Oct

  • 16

    Dec

GM

General Motors

$36.32

0.81 (2.28%)

13:23
10/15/19
10/15
13:23
10/15/19
13:23
Periodicals
GM, UAW said to have agreement on temp worker arrangement, Bloomberg reports »

GM has agreed to make…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

LYFT

Lyft

$40.61

0.84 (2.11%)

13:21
10/15/19
10/15
13:21
10/15/19
13:21
Rumors
Rumor moving shares of Lyft »

Rumor: Lyft moves up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Oct

  • 07

    Nov

  • 19

    Nov

USFD

US Foods

$39.29

-1.28 (-3.16%)

13:19
10/15/19
10/15
13:19
10/15/19
13:19
Recommendations
US Foods analyst commentary  »

US Foods chief supply…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Nov

  • 12

    Nov

COST

Costco

$298.24

0.69 (0.23%)

13:19
10/15/19
10/15
13:19
10/15/19
13:19
Downgrade
Costco rating change  »

Costco downgraded to Hold…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

13:17
10/15/19
10/15
13:17
10/15/19
13:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FOX

Fox Corp.

$31.37

0.33 (1.06%)

, FOXA

Fox Corp.

$31.62

0.21 (0.67%)

13:16
10/15/19
10/15
13:16
10/15/19
13:16
Periodicals
Shari Redstone considers plan to launch Fox News rival, THR says »

As the merger between…

FOX

Fox Corp.

$31.37

0.33 (1.06%)

FOXA

Fox Corp.

$31.62

0.21 (0.67%)

CBS

CBS

$38.17

0.24 (0.63%)

CBS.A

$41.77

(0.00%)

VIA

Viacom

$25.28

0.015 (0.06%)

VIAB

Viacom

$22.87

0.145 (0.64%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 06

    Nov

  • 06

    Nov

  • 12

    Nov

  • 12

    Nov

  • 14

    Nov

  • 14

    Nov

  • 14

    Nov

  • 14

    Nov

$NYE

NYSE Market Internals

$0.00

(0.00%)

13:16
10/15/19
10/15
13:16
10/15/19
13:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WE

We Company

$0.00

(0.00%)

13:12
10/15/19
10/15
13:12
10/15/19
13:12
Periodicals
Breaking Periodicals news story on We Company »

WeWork loses…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RDS.A

Royal Dutch Shell

$57.92

0.08 (0.14%)

, RDS.B

Royal Dutch Shell

$58.44

0.14 (0.24%)

13:06
10/15/19
10/15
13:06
10/15/19
13:06
Periodicals
Shell CEO still sees big opportunties for investors in oil and gas, Reuters says »

Royal Dutch Shell CEO Ben…

RDS.A

Royal Dutch Shell

$57.92

0.08 (0.14%)

RDS.B

Royal Dutch Shell

$58.44

0.14 (0.24%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VKTX

Viking Therapeutics

$6.56

0.17 (2.66%)

13:05
10/15/19
10/15
13:05
10/15/19
13:05
Options
Viking Therapeutics call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CNPOF

Canopy Rivers

$0.00

(0.00%)

13:02
10/15/19
10/15
13:02
10/15/19
13:02
Hot Stocks
Canopy Rivers portfolio company receives Health Canada license amendment »

Canopy Rivers announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CS

Credit Suisse

$12.26

0.28 (2.34%)

13:02
10/15/19
10/15
13:02
10/15/19
13:02
Periodicals
Credit Suisse eyes adding more advisers to billionaire clients, Bloomberg says »

Credit Suisse is seeking…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

CHGG

Chegg

$32.76

0.12 (0.37%)

13:02
10/15/19
10/15
13:02
10/15/19
13:02
Hot Stocks
Law firm initiates investigation into data breach at Chegg »

Federman & Sherwood,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Nov

  • 13

    Nov

CRWD

Crowdstrike

$55.38

0.87 (1.60%)

13:00
10/15/19
10/15
13:00
10/15/19
13:00
Recommendations
Crowdstrike analyst commentary  »

Crowdstrike should be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

13:00
10/15/19
10/15
13:00
10/15/19
13:00
General news
Treasury Action: yields continue to rise »

Treasury Action: yields…

FB

Facebook

$189.25

5.96 (3.25%)

, V

Visa

$178.66

1.31 (0.74%)

12:58
10/15/19
10/15
12:58
10/15/19
12:58
Periodicals
Facebook advances Libra amid backer mutiny, Business Insider says »

Facebook (FB) took…

FB

Facebook

$189.25

5.96 (3.25%)

V

Visa

$178.66

1.31 (0.74%)

MA

MasterCard

$278.77

2.29 (0.83%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 24

    Oct

  • 27

    Oct

  • 29

    Oct

  • 29

    Oct

  • 30

    Oct

12:55
10/15/19
10/15
12:55
10/15/19
12:55
Conference/Events
Morgan Stanley analysts to hold an analyst/industry conference call »

Executive Director of…

APHA

Aphria

$5.40

1.07 (24.71%)

12:51
10/15/19
10/15
12:51
10/15/19
12:51
Recommendations
Aphria analyst commentary  »

Seaport Global says…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Oct

  • 12

    Nov

GOOG

Alphabet

$1,240.28

22.05 (1.81%)

, GOOGL

Alphabet Class A

$1,240.59

22.98 (1.89%)

12:44
10/15/19
10/15
12:44
10/15/19
12:44
Hot Stocks
Google Stadia launches on November 19th »

In a tweet, the Google…

GOOG

Alphabet

$1,240.28

22.05 (1.81%)

GOOGL

Alphabet Class A

$1,240.59

22.98 (1.89%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

  • 27

    Oct

  • 28

    Oct

  • 28

    Oct

  • 29

    Oct

GOOG

Alphabet

$1,240.62

22.39 (1.84%)

, GOOGL

Alphabet Class A

$1,241.32

23.71 (1.95%)

12:40
10/15/19
10/15
12:40
10/15/19
12:40
Hot Stocks
Google announces Nest Wifi system »

Alphabet's Google…

GOOG

Alphabet

$1,240.62

22.39 (1.84%)

GOOGL

Alphabet Class A

$1,241.32

23.71 (1.95%)

TGT

Target

$111.99

0.85 (0.76%)

BBY

Best Buy

$68.65

-0.055 (-0.08%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

  • 27

    Oct

  • 28

    Oct

  • 28

    Oct

  • 29

    Oct

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.